重组组织型纤溶酶原激活剂溶栓治疗脑梗死患者的临床效果观察  

To Observe the Clinical Effect of Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator (RT-PA) in Patients with Cerebral Infarction

作　　者：王娇 WANG Jiao(Department of Neurology,Shenyang First People's Hospital,Shenyang 110000,China)

机构地区：[1]沈阳市第一人民医院神经内科,辽宁沈阳110000

出　　处：《中国医药指南》2022年第16期92-94,共3页Guide of China Medicine

摘　　要：目的 探究对脑梗死患者开展溶栓治疗过程中应用重组组织型纤溶酶原激活剂(rt-PA)进行干预的临床效果。方法 随机抽取88例脑梗死患者纳入试验研究范围,其均于2017年10月至2019年10月入我院接受诊治,采用等量数字随机方式进行分组,分别采用重组组织型纤溶酶原激活剂(试验组,n=44)及阿司匹林联合巴曲酶(对照组,n=44)进行溶栓治疗,对照组治疗方法为选取阿司匹林注射液给予患者静脉滴注或者是肌内注射;首次选取巴曲酶注射液10 BU,后续将用药剂量维持在5 BU,每隔2 d为患者展开一次药物干预;试验组治疗方法为选取重组组织型纤溶酶原激活剂16 mg,将其和无菌注射用水3 mL混合在一起,给予患者静脉注射,比较治疗效果。结果 试验组治疗前的神经功能缺损评分及肢体功能障碍评分与对照组比较差异不显著,P> 0.05;治疗1 d后、5 d后和15 d后,试验组的神经功能缺损评分及肢体功能障碍评分均显著优于对照组,差异显著,P <0.05。试验组发生大面积脑出血、再次脑梗死及植物生存的不良事件发生概率显著低于对照组,差异显著,P <0.05。结论 应用重组组织型纤溶酶原激活剂对脑梗死患者开展溶栓治疗,有利于改善患者的神经功能及运动功能,降低不良事件的发生概率,临床疗效更显著,安全性更高。Objective To explore the clinical effect of recombinant tissue plasminogen activator in thrombolytic therapy for patients with cerebral infarction.Methods A random sample of 88 patients with cerebral infarction in experimental research scope.They were all admitted to our hospital for diagnosis and treatment from October 2017 to October 2019,using equivalent digital random grouping,respectively,using the original activator recombinant tissue type fibrinolytic enzyme(the experimental group,n=44) and aspirin combined the enzyme(the control group,n=44)thrombolytic therapy,the control group was given aspirin injection intravenously or intramuscularly.Batroxase injection 10 BU was selected for the first time,and the drug dose was maintained at 5 BU afterwards,and drug intervention was carried out for patients every 2 days.The treatment method of the experimental group was to select 16 mg of recombinant tissue plasminogen activator,mix it with 3 mL of sterile water for injection,give patients intravenous injection,and analyze the therapeutic effect.Results There was no significant difference in neurological deficit score and limb dysfunction score between the experimental group and the control group before treatment(P>0.05).After 1,5 and 15 days of treatment,the neurological deficit score and limb dysfunction score of the experimental group were significantly better than the control group(P<0.05).The incidence probability of large area cerebral hemorrhage,recurrent cerebral infarction and plant survival in the experimental group was significantly lower than that in the control group(P<0.05).Conclusion Thrombolytic therapy with recombinant tissue plasminogen activator in patients with cerebral infarction is beneficial to improve the neurological function and motor function of patients,reduce the probability of adverse events,and has more significant clinical efficacy and higher safety,which has the value of popularization.

关 键 词：脑梗死 溶栓治疗 重组组织型纤溶酶原激活剂 神经功能缺损 肢体功能障碍 

分 类 号：R473.74[医药卫生—护理学]